|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2011-1-10
|
|
pubmed:abstractText |
Ischemic cerebrovascular accidents remain a leading cause of morbidity and mortality. Thrombolytic therapy for acute ischemic stroke within 3h of symptom onset of highly select patients has been advocated by some groups since 1995, but trials have yielded inconsistent outcomes. One recent trial demonstrated significant improvement when the therapeutic window was extended to 4.5h.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0736-4679
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright © 2011 Elsevier Inc. All rights reserved.
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
40
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
82-92
|
|
pubmed:dateRevised |
2011-10-26
|
|
pubmed:meshHeading |
pubmed-meshheading:20576390-Acute Disease,
pubmed-meshheading:20576390-Adolescent,
pubmed-meshheading:20576390-Adult,
pubmed-meshheading:20576390-Aged,
pubmed-meshheading:20576390-Brain Ischemia,
pubmed-meshheading:20576390-Evidence-Based Medicine,
pubmed-meshheading:20576390-Female,
pubmed-meshheading:20576390-Humans,
pubmed-meshheading:20576390-Middle Aged,
pubmed-meshheading:20576390-Randomized Controlled Trials as Topic,
pubmed-meshheading:20576390-Stroke,
pubmed-meshheading:20576390-Thrombolytic Therapy,
pubmed-meshheading:20576390-Time Factors,
pubmed-meshheading:20576390-Tissue Plasminogen Activator,
pubmed-meshheading:20576390-Treatment Outcome
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Thrombolytic therapy for acute ischemic stroke beyond three hours.
|
|
pubmed:affiliation |
Washington University School of Medicine, St. Louis, MO, USA.
|
|
pubmed:publicationType |
Journal Article,
Case Reports,
Meta-Analysis
|
